PMID- 23103368
OWN - NLM
STAT- MEDLINE
DCOM- 20130718
LR  - 20141120
IS  - 1938-0666 (Electronic)
IS  - 1526-8209 (Linking)
VI  - 13
IP  - 1
DP  - 2013 Feb
TI  - Influence of neoadjuvant chemotherapy on HER2/neu status in invasive breast 
      cancer.
PG  - 53-60
LID - S1526-8209(12)00215-7 [pii]
LID - 10.1016/j.clbc.2012.09.011 [doi]
AB  - INTRODUCTION: Reliably estimating HER2/neu expression in breast cancer is 
      important for predicting patient prognosis and optimizing adjuvant therapeutic 
      strategies. In this retrospective cohort study, effects of NAC on HER2/neu status 
      in invasive breast cancer were evaluated, and the related factors were analyzed. 
      PATIENTS AND METHODS: One hundred thirty-one patients with primary breast cancer 
      were treated with anthracycline- and/or taxane-based NAC. HER2/neu status was 
      evaluated by IHC on core needle biopsies of primary tumors before NAC and 
      surgical resection specimens of post-NAC residual breast cancers or 
      tumor-positive axillary lymph nodes. Thirty-two pairs of specimens with 
      discordant HER2/neu IHC scores were analyzed by fluorescence in situ 
      hybridization (FISH). RESULTS: A significant difference in HER2/neu status by IHC 
      between core needle biopsies and surgical resection specimens in patients 
      receiving NAC was observed. After NAC, 23.4% (29 of 124) of tumors showed 
      downregulated HER2/neu expression by IHC. Alterations of HER2/neu IHC scores did 
      not significantly correlate with tumor subtype, pathologic response to NAC, 
      adjuvant regimen, or time interval from the last chemotherapy to surgery. 
      HER2/neu protein overexpression level was associated with favorable pathologic 
      response to anthracycline and taxane-based chemotherapy. However, tumors with 
      altered HER2/neu IHC scores after NAC revealed stable HER2/neu gene 
      amplification/nonamplification by FISH analysis. CONCLUSION: Neoadjuvant 
      chemotherapy for breast carcinoma resulted in the HER2/neu status alteration by 
      IHC, but they have stable gene amplification status by FISH. HER2/neu protein 
      overexpression indicated greater sensitivity to neoadjuvant anthracycline- and 
      taxane-based chemotherapy. Thus, retesting HER2/neu IHC status in residual tumors 
      after NAC should be considered in order to optimize adjuvant systemic therapy.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
FAU - Li, Peifeng
AU  - Li P
AD  - State Key Laboratory of Cancer Biology, Department of Pathology, Xijing Hospital 
      and School of Basic Medicine, Fourth Military Medical University, Xi'an, P.R. 
      China.
FAU - Liu, Tantan
AU  - Liu T
FAU - Wang, Yingmei
AU  - Wang Y
FAU - Shao, Shuai
AU  - Shao S
FAU - Zhang, Weichen
AU  - Zhang W
FAU - Lv, Yang
AU  - Lv Y
FAU - Yi, Jun
AU  - Yi J
FAU - Wang, Zhe
AU  - Wang Z
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20121026
PL  - United States
TA  - Clin Breast Cancer
JT  - Clinical breast cancer
JID - 100898731
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adenocarcinoma, Mucinous/drug therapy/metabolism/pathology
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Breast Neoplasms/*drug therapy/metabolism/pathology
MH  - Carcinoma, Basal Cell/drug therapy/metabolism/pathology
MH  - Carcinoma, Ductal, Breast/*drug therapy/metabolism/pathology
MH  - Carcinoma, Lobular/drug therapy/metabolism/pathology
MH  - Case-Control Studies
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Immunoenzyme Techniques
MH  - In Situ Hybridization, Fluorescence
MH  - Lymphatic Metastasis
MH  - Middle Aged
MH  - *Neoadjuvant Therapy
MH  - Neoplasm Invasiveness
MH  - Neoplasm Staging
MH  - Prognosis
MH  - Receptor, ErbB-2/*genetics/*metabolism
MH  - Retrospective Studies
EDAT- 2012/10/30 06:00
MHDA- 2013/07/19 06:00
CRDT- 2012/10/30 06:00
PHST- 2012/03/24 00:00 [received]
PHST- 2012/09/08 00:00 [revised]
PHST- 2012/09/20 00:00 [accepted]
PHST- 2012/10/30 06:00 [entrez]
PHST- 2012/10/30 06:00 [pubmed]
PHST- 2013/07/19 06:00 [medline]
AID - S1526-8209(12)00215-7 [pii]
AID - 10.1016/j.clbc.2012.09.011 [doi]
PST - ppublish
SO  - Clin Breast Cancer. 2013 Feb;13(1):53-60. doi: 10.1016/j.clbc.2012.09.011. Epub 
      2012 Oct 26.